DPP‐4 inhibition and islet function
Author:
Open Access
- 13 December 2011
- journal article
- review article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 3 (1) , 3-10
Abstract
During recent years, dipeptidyl peptidase‐4 (DPP‐4) inhibition has been included in the clinical management of type 2 diabetes, both as monotherapy and as add‐on to several other therapies. DPP‐4 inhibition prevents the inactivation of the incretin hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1). This results in stimulation of insulin secretion and inhibition of glucagon secretion, and there is also a potential β‐cell preservation effect, as judged from rodent studies; that is, it might target the key islet dysfunction in the disease. In type 2 diabetes. This reduces 24‐h glucose levels and reduces HbA1c by ≈ 0.8–1.1% from baseline levels of 7.7–8.5%. DPP‐4 inhibition is safe, with a very low risk for adverse events including hypoglycemia, and it prevents weight gain. The present review summarizes the studies on the influence of DPP‐4 inhibition on islet function. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2011.00184.x, 2012)Keywords
This publication has 66 references indexed in Scilit:
- Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trialDiabetologia, 2011
- Saxagliptin for type 2 diabetesDiabetes, Metabolic Syndrome and Obesity, 2010
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering ActionDiabetes, 2010
- Emerging treatment options for type 2 diabetesBritish Journal of Clinical Pharmacology, 2010
- Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin MonotherapyDiabetes Care, 2010
- Impact of Sitagliptin on Markers of β-cell Function: A Meta-AnalysisThe American Journal of the Medical Sciences, 2009
- Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2009
- Mechanisms of action of glucagon-like peptide 1 in the pancreasPharmacology & Therapeutics, 2007
- Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- GLP-1 and GLP-17-36 AmidePancreas, 1991